Autism Spectrum Disorder Asd

Introducing our new Portfolio Addition: Neurotech International (ASX: NTI)

Next Investors Sep 18, 2023

We are excited to announce our latest investment in Neurotech International (ASX: NTI), an early-stage biotech targeting rare neurological disorders in children; the company is primed for three major share price catalysts in the form of clinical trial results over the next 6-12 months, echoing a strategic approach similar to Neuren Pharmaceuticals, which experienced a 1,300% share price rise over three years.

Neurotech embarks on ground-breaking ASD trials

Finfeed Archived May 05, 2021

Neurotech International (ASX: NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with ASD.